News | Stent Grafts | April 06, 2017

Endologix Announces Enrollment of First Patients in ELEVATE IDE Clinical Study

Trial will evaluate safety and effectiveness of Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms

April 6, 2017 — Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study.

ELEVATE IDE is the company’s pivotal clinical trial to evaluate the safety and effectiveness of the Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms (AAAs). The trial is approved to enroll 75 patients at up to 12 centers in the United States. The first procedure was performed by Steve Henao, M.D., chief, Division of Vascular Surgery at New Mexico Heart Institute.

The study principal investigator, Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic commented, “We are excited to start treating patients in the ELEVATE IDE trial. The polymer technology in the device allows for active sealing in the aortic neck. The polymer sealing ring has proven durability in maintaining aneurysm exclusion to five years as reported in the Global Ovation Pivotal Trial. The repositioning of the sealing ring to 7mm below the top of the fabric will allow treatment of more challenging and complex anatomies in this trial.”

Ovation Alto is the newest device in the Ovation platform of abdominal stent graft systems, which has proven clinical results reported from the Ovation global pivotal trial and European Post-Market Registry. Ovation Alto expands endovascular aortic repair (EVAR) to treat more patients on IFU. This is achieved by the conformable O-rings with CustomSeal polymer that have been repositioned near the top of the endograft, providing seal just below the renal arteries.

The Ovation platform is the lowest profile U.S. Food and Drug Administration (FDA)-approved EVAR device, and it has been used successfully in the treatment of over 12,000 patients worldwide. Ovation Alto is an investigational device and currently not approved in any market.

Endologix CEO John McDermott said the company expects Ovation Alto could be available in the U.S. in 2019, based on the anticipated enrollment timeline.

For more information: www.endologix.com

Related Content

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future.

Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images

News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC)...
Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research te
Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...